Randomized trial of high‐dose interferon‐α‐2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy

The aim of this study was to compare the efficacy of high‐dose interferon (IFN)‐α‐2b with standard dose of IFN‐α‐2b in combination with ribavirin (RBV) for patients with chronic hepatitis C virus (HCV) infection, and to investigate the predictive factors associated with virological response. Two hundred Japanese patients with high HCV viral load (>100 KIU/ml) were randomized to 6 or 10 mega units (MU) of 24‐week IFN‐α‐2b with RBV. Predictive factors were investigated; including pretreatment amino acid (aa) sequences of the core region and the IFN‐sensitive determining region (ISDR). The sustained virological response rate was not different in the two groups (24% vs. 30%) but the incidence of depression was significantly higher in the 10 MU group than 6 MU group (7% vs. 0%, P = 0.02). Younger age (<60) and HCV genotype (2a/b) were significant predictors of sustained virological response. In patients infected with genotype 1b, substitutions of core aa 70 and/or 91 were predictive for non‐virological response (P < 0.001), and substitutions in the ISDR was observed frequently in virological responders. Early viral kinetics study showed that serum HCV core antigen decreased more slowly in both patients with aa 70 and/or 91 substitutions in the core and with absence of substitutions in the ISDR. In conclusion, the use of a higher dose of IFN‐α‐2b in combination with RBV did not improve virological response but resulted in higher incidence of depression. Amino acid substitutions in the core and ISDR are predictive of virological response to the therapy in patients with genotype 1b and high viral load. J. Med. Virol. 81:640–649, 2009 © 2009 Wiley‐Liss, Inc.

[1]  A. Moya,et al.  Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment , 2008, Journal of medical virology.

[2]  Yoshiyuki Suzuki,et al.  Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b , 2007, Journal of medical virology.

[3]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[4]  Tara L. Kieffer,et al.  Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C , 2007, Hepatology.

[5]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[6]  S. Zeuzem,et al.  SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. , 2007, Gastroenterology.

[7]  Yoshiyuki Suzuki,et al.  Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. , 2007, Journal of hepatology.

[8]  F. Penin,et al.  The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region. , 2007, The Journal of infectious diseases.

[9]  C. Marcantonio,et al.  Repression of Interferon Regulatory Factor 1 by Hepatitis C Virus Core Protein Results in Inhibition of Antiviral and Immunomodulatory Genes , 2006, Journal of Virology.

[10]  S. Zeuzem,et al.  Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. , 2006, Gastroenterology.

[11]  Wenyu Lin,et al.  Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 Domain , 2006, Journal of Virology.

[12]  R. Andrade,et al.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.

[13]  L. Messerini,et al.  Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. , 2006, Gastroenterology.

[14]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[15]  Yoshiyuki Suzuki,et al.  Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load , 2006, Journal of medical virology.

[16]  Yoshiyuki Suzuki,et al.  Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.

[17]  A. Moreau,et al.  Mutations within the Hepatitis C Virus Genotype 1b E2-PePHD Domain Do Not Correlate with Treatment Outcome , 2005, Journal of Clinical Microbiology.

[18]  P Martus,et al.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences , 2004, Gut.

[19]  H. Van Vlierberghe,et al.  Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. , 2004, Journal of hepatology.

[20]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[21]  J. Hoofnagle,et al.  Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin , 2003, Hepatology.

[22]  Stanley M. Lemon,et al.  Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease , 2003, Science.

[23]  L. Terracciano,et al.  Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. , 2003, Gastroenterology.

[24]  P. Heinrich,et al.  IFN‐α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling‐3 , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[26]  A. Craxì,et al.  Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high‐dose interferon induction , 2002, Journal of viral hepatitis.

[27]  C. Datz,et al.  Combination of interferon induction therapy and ribavirin in chronic hepatitis C , 2001, Hepatology.

[28]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[29]  X. Forns,et al.  Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C , 2001, Journal of medical virology.

[30]  S. Hadziyannis,et al.  Induction interferon therapy in naïve patients with chronic hepatitis C: increased end‐of‐treatment virological responses but absence of long‐term benefit , 2001, Alimentary pharmacology & therapeutics.

[31]  K. Chayama,et al.  Association of amino acid sequence in the PKR‐eIF2 phosphorylation homology domain and response to interferon therapy , 2000, Hepatology.

[32]  H. Conjeevaram,et al.  A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype , 2000, American Journal of Gastroenterology.

[33]  S. Polyak,et al.  The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. , 2000, The Journal of infectious diseases.

[34]  D. R. Taylor,et al.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.

[35]  K. Chayama,et al.  Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region , 1999, Journal of medical virology.

[36]  S. Yagi,et al.  Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core Antigen , 1999, Journal of Clinical Microbiology.

[37]  D. Häussinger,et al.  Prognosis of chronic hepatitis c: Results of a large, prospective cohort study , 1998, Hepatology.

[38]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[39]  J. Mullins,et al.  Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection , 1998, Journal of Virology.

[40]  M. Katze,et al.  Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. , 1997, Virology.

[41]  K. Chayama,et al.  Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection , 1997, Hepatology.

[42]  E. Schiff,et al.  Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial , 1996, Hepatology.

[43]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[44]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[45]  T. Sugimura,et al.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Purcell,et al.  Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.